READ: ARW ON RNA

61. Overcoming CGT Potency Assay Woes: 4 Best Practices 12/21/2022

    Here, I share a few of the actionable takeaways I walked away with from the ARM/ASGCT potency assay working session in the hopes they will be a complementary exploration of the analytical challenge impacting every ATMP company.

62. CGT Potency Assays: When Will We Wake Up From The Nightmare? 12/12/2022

    Here, I offer my biggest takeaways from a recent ARM/ASGCT workshop on one of the most popular topics to gossip about both in and outside the analytical labs: Potency assays. In part one of this two-part article, I start by unpacking what I see as the most prominent knowledge gaps and questions underpinning the industry’s potency assay challenge.

63. mRNA & RNA Therapeutics In 2023: Where Do We Go From Here? 12/7/2022

    To figure out what the future holds for companies in the RNA sector of the ATMP space, I sat down with four executives to discuss their wildest hopes, dreams, and expectations. As you’ll note, there is no shortage of work facing the RNA therapeutics industry in the year(s) ahead. But there’s also a lot for which we can hope.

64. A (More) Mature mRNA Therapeutics Industry: 4 Best Practices To Get There 9/27/2022

    Throughout the two-day mRNA Therapeutics Summit, there were four key takeaways that clearly demonstrated how the mRNA industry could incrementally achieve one speaker's industry prediction that, within the next 10 years, every person in the world will have had the opportunity to benefit from mRNA.

65. Equitable mRNA Therapies Demands Multi-Faceted Understanding Of Access & Innovation 9/19/2022

    This article is the final installment in a four-part series unpacking several of the best practices shared during the mRNA Therapeutics Summit, which took place in Boston on July 27 & 28, 2022. 

66. mRNA Delivery Is More Than Just The Vehicle: Think Outside — & Inside — The LNP 9/14/2022

    This article is part three of a four-part series unpacking my biggest takeaways from the mRNA Therapeutics Summit, which took place in Boston on July 27 & 28, 2022.

67. To Advance An mRNA “Platform,” Forget Traditional Operational Structures 9/11/2022

    This article is **part** **two** of a four-part series unpacking several best practices I gleaned from the mRNA Therapeutics Summit, which took place in Boston on July 27 & 28, 2022.

68. Don't Get Uppity: Match mRNA Science To Your Capabilities — And Vice Versa 9/6/2022

    This article is part one of a four-part series unpacking four of my biggest takeaways from the mRNA Therapeutics Summit, which took place in Boston on July 27 & 28, 2022.

69. What Violin Making Can Teach Us About mRNA Therapeutic Quality 8/8/2022

    Managing the mRNA supply chain and working in mRNA process development may not look anything like the work a luthier does to hew an instrument from an ancient spruce tree. But violin craftmanship actually serves as a fantastic metaphor for the challenging work the mRNA therapeutics space is tackling in sourcing and qualifying raw materials and optimizing the critical IVT reaction.

70. What Playing RISK Can Teach Us About mRNA Manufacturing 7/11/2022

    On the surface, it may seem as though there is little in common between playing a board game and manufacturing mRNA therapeutics. But as I see it, strategizing, playing, and winning at RISK is highly analogous to the challenges mRNA therapeutics companies will face as they strive to achieve a well-controlled and understood commercial scale manufacturing process.